Obstructive Sleep Apnea and Atherosclerosis

Progress in Cardiovascular Diseases

Volumn 51, Issue 5, 2009, Pages 400-410

  Lévy, Patrick ^a,b,c,d   Pépin, Jean Louis ^a,b,c,d   Arnaud, Claire ^a,b,c,d   Baguet, Jean Philippe ^a,b,c,d   Dematteis, Maurice ^a,b,c,d   Mach, François ^a,b,c,d  

^a University Grenoble Alpes   (France)

^b EFCR   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; ENDOTHELIN; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CHOLESTEROL DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSLIPIDEMIA; ELECTRON BEAM TOMOGRAPHY; ENZYME RELEASE; GLYCEMIC CONTROL; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPOXIA; INFLAMMATION; INFLAMMATORY CELL; INSULIN RESISTANCE; LEUKOCYTE; LEUKOCYTE ROLLING; LIPID METABOLISM; LIPID PEROXIDATION; MICROALBUMINURIA; MORTALITY; NONHUMAN; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; POSITRON EMISSION TOMOGRAPHY; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLEEP APNEA SYNDROME; SLEEP DISORDER; STROKE; T LYMPHOCYTE ACTIVATION; VASCULARIZATION;

ANIMALS; ANOXIA; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE;

EID: 60949108252     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2008.03.001     Document Type: Article

References (96)

1. Young T., Peppard P.E., and Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165 (2002) 1217-1239
2. Young T., Palta M., Dempsey J., et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328 (1993) 1230-1235
3. Teran-Santos J., Jimenez-Gomez A., and Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 340 (1999) 847-851
4. Levy P., Pepin J.L., and McNicholas W.T. Should all sleep apnoea patients be treated? Yes. Sleep Med Rev 6 (2002) 17-26 [discussion 7]
5. Marin J.M., Carrizo S.J., Vicente E., et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365 (2005) 1046-1053
6. Pepperell J.C., Ramdassingh-Dow S., Crosthwaite N., et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 359 (2002) 204-210
7. Drager L.F., Bortolotto L.A., Lorenzi M.C., et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 172 (2005) 613-618
8. Baguet J.P., Hammer L., Levy P., et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 128 (2005) 3407-3412
9. Lavie P., Herer P., Peled R., et al. Mortality in sleep apnea patients: a multivariate analysis of risk factors. Sleep 18 (1995) 149-157
10. Lavie P., Lavie L., and Herer P. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. Eur Respir J 25 (2005) 514-520
11. Yaggi H.K., Concato J., Kernan W.N., et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353 (2005) 2034-2041
12. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
13. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
14. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
15. Ohga E., Tomita T., Wada H., et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 94 (2003) 179-184
16. Ursavas A., Karadag M., Rodoplu E., et al. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 74 (2006) 525-532
17. Ohga E., Nagase T., Tomita T., et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 87 (1999) 10-14
18. Braunersreuther V., and Mach F. Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches. Cell Mol Life Sci 63 (2006) 2079-2088
19. Butcher E.C. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67 (1991) 1033-1036
20. Nacher M., Serrano-Mollar A., Farre R., et al. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 155 (2007) 93-96
21. Pignoli P., Tremoli E., Poli A., et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
22. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 23 (2007) 75-80
23. Salonen J.T., and Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 11 (1991) 1245-1249
24. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
25. Fathi R., Haluska B., Isbel N., et al. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 43 (2004) 616-623
26. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
27. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
28. Lonn E., Yusuf S., Dzavik V., et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
29. Zanchetti A., Bond M.G., Hennig M., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106 (2002) 2422-2427
30. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003) 2294-2303
31. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27 (2006) 2588-2605
32. Criqui M.H., Coughlin S.S., and Fronek A. Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study. Circulation 72 (1985) 768-773
33. Kondos G.T., Hoff J.A., Sevrukov A., et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 107 (2003) 2571-2576
34. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48 (2006) 1825-1831
35. Wachtell K., Ibsen H., Olsen M.H., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139 (2003) 901-906
36. Savransky V., Nanayakkara A., Li J., et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 175 (2007) 1290-1297
37. Allahdadi K.J., Walker B.R., and Kanagy N.L. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension 45 (2005) 705-709
38. Lefebvre B., Godin-Ribuot D., Joyeux-Faure M., et al. Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat. Respir Physiol Neurobiol 150 (2006) 278-286
39. Troncoso Brindeiro C.M., da Silva A.Q., Allahdadi K.J., et al. Reactive oxygen species contribute to sleep apnea-induced hypertension in rats. Am J Physiol Heart Circ Physiol 293 (2007) H2971-H2976
40. Julien C., Bayat S., and Levy P. Vascular reactivity to norepinephrine and acetylcholine after chronic intermittent hypoxia in mice. Respir Physiol Neurobiol 139 (2003) 21-32
41. Dematteis M., Julien C., Guillermet C., et al. Intermittent Hypoxia Induces Early Functional Cardiovascular Remodeling in Mice. Am J Respir Crit Care Med 177 (2008) 227-235
42. Tahawi Z., Orolinova N., Joshua I.G., et al. Altered vascular reactivity in arterioles of chronic intermittent hypoxic rats. J Appl Physiol 90 (2001) 2007-2013 [discussion 0]
43. Fletcher E.C., Lesske J., Qian W., et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 19 (1992) 555-561
44. Lai C.J., Yang C.C., Hsu Y.Y., et al. Enhanced sympathetic outflow and decreased baroreflex sensitivity are associated with intermittent hypoxia-induced systemic hypertension in conscious rats. J Appl Physiol 100 (2006) 1974-1982
45. Lin M., Liu R., Gozal D., et al. Chronic intermittent hypoxia impairs baroreflex control of heart rate but enhances heart rate responses to vagal efferent stimulation in anesthetized mice. Am J Physiol Heart Circ Physiol 293 (2007) H997-H1006
46. Fletcher E.C. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol 119 (2000) 189-197
47. Kanagy N.L., Walker B.R., and Nelin L.D. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 37 (2001) 511-515
48. Fletcher E.C., Bao G., and Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 34 (1999) 309-314
49. Morgan B.J. Vascular consequences of intermittent hypoxia. Adv Exp Med Biol 618 (2007) 69-84
50. Eguchi K., Pickering T.G., Hoshide S., et al. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am J Hypertens 41 (2008) 443-450
51. Gorostidi M., Sobrino J., Segura J., et al. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens 25 (2007) 977-984
52. Cuspidi C., Meani S., Valerio C., et al. Nocturnal non-dipping pattern in untreated hypertensives at different cardiovascular risk according to the 2003 ESH/ESC guidelines. Blood Press 15 (2006) 37-44
53. Polotsky V.Y., Li J., Punjabi N.M., et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552 (2003) 253-264
54. Li J., Thorne L.N., Punjabi N.M., et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97 (2005) 698-706
55. Li J., Bosch-Marce M., Nanayakkara A., et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 25 (2006) 450-457
56. Li J., Savransky V., Nanayakkara A., et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 102 (2007) 557-563
57. Iiyori N., Alonso L.C., Li J., et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 175 (2007) 851-857
58. Vgontzas A.N., Bixler E.O., and Chrousos G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 9 (2005) 211-224
59. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144 (2003) 2195-2200
60. Foster G.E., Poulin M.J., and Hanly P.J. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 92 (2007) 51-65
61. Greenberg H., Ye X., Wilson D., et al. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343 (2006) 591-596
62. Ryan S., Taylor C.T., and McNicholas W.T. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112 (2005) 2660-2667
63. Dyugovskaya L., Lavie P., and Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165 (2002) 934-939
64. Lavie L., Dyugovskaya L., and Lavie P. Sleep-apnea-related intermittent hypoxia and atherogenesis: adhesion molecules and monocytes/endothelial cells interactions. Atherosclerosis 183 (2005) 183-184
65. Cahan C., Decker M.J., Arnold J.L., et al. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol 79 (1995) 1278-1285
66. Hoffstein V., Herridge M., Mateika S., et al. Hematocrit levels in sleep apnea. Chest 106 (1994) 787-791
67. von Kanel R., Le D.T., Nelesen R.A., et al. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 19 (2001) 1445-1451
68. McGuire M., and Bradford A. Chronic intermittent hypoxia increases haematocrit and causes right ventricular hypertrophy in the rat. Respir Physiol 117 (1999) 53-58
69. McGuire M., and Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J 18 (2001) 279-285
70. Gottlieb D.J., Redline S., Nieto F.J., et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. Sleep 29 (2006) 1009-1014
71. Gangwisch J.E., Heymsfield S.B., Boden-Albala B., et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 47 (2006) 833-839
72. Gottlieb D.J., Punjabi N.M., Newman A.B., et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 165 (2005) 863-867
73. Knutson K.L., Ryden A.M., Mander B.A., et al. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 166 (2006) 1768-1774
74. Minoguchi K., Yokoe T., Tazaki T., et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 172 (2005) 625-630
75. Turmel J., Series F., Boulet L.P., et al. Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study. Int J Cardiol (2008) [Electronic puclication ahead of print]
76. Drager L.F., Bortolotto L.A., Figueiredo A.C., et al. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 176 (2007) 706-712
77. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860
78. Shamsuzzaman A.S., Winnicki M., Lanfranchi P., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105 (2002) 2462-2464
79. Yokoe T., Minoguchi K., Matsuo H., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107 (2003) 1129-1134
80. Yao M., Tachibana N., Okura M., et al. The relationship between sleep-disordered breathing and high-sensitivity C-reactive protein in Japanese men. Sleep 29 (2006) 661-665
81. Taheri S., Austin D., Lin L., et al. Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing. Sleep 30 (2007) 991-996
82. Guilleminault C., Kirisoglu C., and Ohayon M.M. C-reactive protein and sleep-disordered breathing. Sleep 27 (2004) 1507-1511
83. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 7 (2003) 35-51
84. Carpagnano G.E., Kharitonov S.A., Resta O., et al. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 122 (2002) 1162-1167
85. Lavie L., Vishnevsky A., and Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27 (2004) 123-128
86. Lavie L., Lotan R., Hochberg I., et al. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep 26 (2003) 592-595
87. Levy A.P., Zhang L., Miller-Lotan R., et al. Haptoglobin phenotype, sleep-disordered breathing, and the prevalence of cardiovascular disease: the Sleep Heart Health Study. Sleep 28 (2005) 207-213
88. Tan K.C., Chow W.S., Lam J.C., et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 184 (2006) 377-382
89. Tan K.C., Chow W.S., Lam J.C., et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 29 (2006) 329-333
90. Patrice F., Renaud T., Jean-Philippe B., et al. Impairment of serum albumin antioxidant properties in obstructive sleep apnoea syndrome. Eur Respir J (2008) [Electronic puclication ahead of print]
91. Dyugovskaya L., Lavie P., and Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 1051 (2005) 340-350
92. Dyugovskaya L., Lavie P., Hirsh M., et al. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 25 (2005) 820-828
93. Dyugovskaya L., Polyakov A., Lavie P., et al. Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 177 (2008) 544-554 [%R 10.1164/rccm.200705-675OC, Electronic publication 2007 Nov 15]
94. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N Engl J Med 357 (2007) 1841-1854
95. Back M., and Hansson G.K. Leukotriene receptors in atherosclerosis. Ann Med 38 (2006) 493-502
96. Lefebvre B., Pepin J.L., Baguet J.P., et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea. Eur Respir J (2008) [09031936.0137107, Electronic publication ahead of print]